How molecular syndromic panels are reshaping infectious disease diagnostics and what their results don’t show

The panel was negative, the patient was not

The call came just after the respiratory syndromic panel finished running. The panel report was negative; no targets were detected.

But the patient was still getting worse. Fever, escalating oxygen needs, new bilateral infiltrates. The result was useful, but it was not reassuring in the way a negative test result can appear on a report.

The gap between a rapid molecular result and a severely ill patient is a well-known problem in infectious disease diagnostics. Understanding it requires knowing what these panels can and cannot rule out.

Faster, sharper questions 

Molecular syndromic panels have quietly rewritten the daily workflow in many clinical microbiology labs. What used to take days now often comes back in hours, sometimes with a long list of respiratory, gastrointestinal, central nervous system, or bloodstream pathogen targets from a single specimen. Depending on the assay and its target menu, multiplex panel testing can detect pathogens that are difficult to recover using conventional methods. Because these assays detect nucleic acid, they may identify some targets after antimicrobial therapy has reduced the yield of culture. (1)

That speed is real. The appeal is real. Rapid results, when used for the right patient and reviewed quickly, can help stewardship teams reassess broad-spectrum therapy sooner. However, speed can also create a false sense of completeness.

What “negative” really means 

One of the most important things these panels do not do is rule out infection. They rule out the organisms on the panel, in the specimen tested, at the time it was collected. For a clearly ill patient, a negative result should not end the diagnostic workup. It should narrow down the next question.

Fixed target lists, specimen-specific performance, exposure history and local epidemiology all shape how much reassurance a negative result should provide. In those moments, the right question is not “Is the test negative?” but “What might this test be missing?”

Is the specimen appropriate for the syndrome?

Are there key pathogens outside the panel’s scope?

Do we need culture, serology, singleplex tests or something else entirely?

When “positive” doesn’t mean “this is it”  

Positive results carry their own ambiguity. These panel assays detect nucleic acid, not disease. Depending on the organism and the specimen source, a positive result can reflect colonization, prolonged shedding, or a signal that is technically real but clinically uncertain. (1)

A panel might light up with multiple organisms in one sample. One of them may be the driver and another may just be an observer. Reviews of syndromic panel-based testing are clear: A positive result doesn’t necessarily mean the pathogen is causing the current illness, and important co-infections can still hide outside what the panel reports. (2)

Again, the key question is not “Is it positive?” but “Does this fit the patient?”

Tools that sharpen, not replace, judgment 

Syndromic testing has made infectious disease diagnostics faster and, in many situations, more actionable. But the panels are best understood as tools that sharpen decision making, not tools that replace it.

This is where diagnostic stewardship is crucial: Selecting the right test for the right patient, at the right time, then accurately interpreting the results within the clinical setting. Communication between the clinical team and the laboratory is particularly important when the patient's clinical picture and the results do not match. (3)

The panel was negative. The patient was not. The test didn’t close the case; it refined the next diagnostic question.

Three questions to ask when the panel result and clinical picture don’t match 

• Is this organism a known colonizer at this site?
• What important pathogens are outside this panel?
• What test should we order next, given this syndrome?

Acknowledgments:

The opening vignette is a composite scenario informed by published clinical literature; no individual patient is described.

Artificial intelligence tools were used to support language refinement during the drafting of this post. The intellectual content and final responsibility for the post remain entirely the author’s.

This blog post was created for educational purposes only and is NOT meant to be used as medical advice, diagnosis or laboratory consultation. Moreover, clinical decisions should be made only by qualified health care professionals regarding individual patient care.

References

1. Dien Bard J, McElvania E. Panels and Syndromic Testing in Clinical Microbiology. Clin Lab Med. 2020;40(4):393-420.
2. Ramanan P, Bryson AL, Binnicker MJ, et al. Syndromic Panel-Based Testing in Clinical Microbiology. Clin Microbiol Rev. 2017;31(1):e00024-17.
3. Society for Healthcare Epidemiology of America. Diagnostic Stewardship.